Hereditary hyperbilirubinemia: An original study of four cases with review of literature.

Dr. Aarti B. Bhattacharya 1, Dr. Shamima 2, Dr. S K Gupta 3.
1 Professor & 2 Assist. Prof. Pathology Dept. Hind Institute Of Medical Sciences, Safedabad Barabanki (UP) INDIA
3. Associate Prof. Dept. of Skin & VD. Hind Institute Of Medical Sciences, Safedabad Barabanki (UP) INDIA

Abstract: Crigler Najjar Syndrome (CNS) a congenital non hemolytic hyperbilirubinemia is very rare with an incidence of around 1 in 1,000,000 births associated with a complete hepatic deficit of bilirubin glucuronosyltransferase activity. Herein we present a study of four cases: three siblings from the same family and one independent case. All the three siblings of the same family had history of persistent neonatal unconjugated hyperbilirubinemia, out of which the eldest female sibling died of seizures with severe hyperbilirubinemia giving a high suspicion of kernicterus. Second eldest and the youngest son had congenital unconjugated hyperbilirubinemia. The third born male child was normal. The independent case had history of persistent mild hyperbilirubinemia since twelve years of age.

Key words: Unconjugated hyperbilirubinemia, Uridine diphosphate glucuronosyltransferase deficiency, severe jaundice, phototherapy, phenobarbitol, liver transplantation.

I. Introduction:
Crigler Najjar Syndrome is a disorder characterized by familial chronic nonhemolytic unconjugated hyperbilirubinemia caused by genetic lesion. It has two types: Type I CNS and Type II CNS. Type I has recessive transmission [2] while type II has both dominant and recessive traits [1]. Clinically negligible Gilbert’s syndrome is the other familial hyperbilirubinemia disorder with an incidence of 3 to 10 % [3].

II. Material and methods:
The present original study of four cases was conducted at the department of Pathology, Hind Institute of Medical Sciences, Safedabad, Barabanki (UP), India. Patient’s baseline pathological tests were performed along with hemolytic profile, liver function test, liver biopsy and cytogenetic studies with detailed family history including birth history and milestones.

III. Results and Discussion:
Only a few hundred cases of Crigler-Najjar Syndrome have been described in the literature so far. The affected neonate shows early intense jaundice due to unconjugated bilirubin. Physical examination does not reveal any defect. [1,2]

In our study parents of first three cases gave history of consanguineous marriage. The eldest female sibling had severe icterus and jaundice soon after birth (CASE 1). There was no history of preterm delivery or septicemia. The neonate deteriorated and succumbed to seizures on the sixth day post partum. No investigations could be carried out in this case. The other two siblings (second and fourth born males - CASES 2 & 3) developed icterus in infancy. Icterus and jaundice increased under conditions of stress and the physical growth of two was affected. The third born male child was normal. According to our studies the three siblings are seen to have recessive transmission from parents. All the investigations done in these two cases turned out to be within normal limits except for bilirubin levels. The fourth case of the study finally diagnosed as Gilbert’s Syndrome, presented with history of icterus since the age of twelve years with complaint of generalized weakness. The investigation reports are tabulated in Table 1.

### Table 1: Investigations Of The Three Live Cases.

<table>
<thead>
<tr>
<th>INVESTIGATIONS</th>
<th>CASE 2</th>
<th>CASE 3</th>
<th>CASE 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB</td>
<td>13.3 gm%</td>
<td>13.6 gm%</td>
<td>11.4 gm%</td>
</tr>
<tr>
<td>RBC</td>
<td>4.4 millions/ cumm</td>
<td>4.8 millions/ cumm</td>
<td>4.0 millions/cumm</td>
</tr>
<tr>
<td>Reticulocyte count</td>
<td>0.8 %</td>
<td>0.6 %</td>
<td>2.0 %</td>
</tr>
<tr>
<td>MCV</td>
<td>80.0 fl/cumm</td>
<td>82.0 fl/cumm</td>
<td>63.3 fl/cumm</td>
</tr>
<tr>
<td>MCH</td>
<td>27.5 gm/dl</td>
<td>28.0 gm/dl</td>
<td>19.5 gm/dl</td>
</tr>
<tr>
<td>MCHC</td>
<td>33.0 %</td>
<td>33.4 %</td>
<td>31.0 %</td>
</tr>
<tr>
<td>ESR</td>
<td>7 mm at 1 hr</td>
<td>8 mm at 1 hr</td>
<td>11 mm at 1 hr</td>
</tr>
<tr>
<td>TLC</td>
<td>7000 cells/cumm</td>
<td>6,500 cells/cumm</td>
<td>6,700 cells/cumm</td>
</tr>
</tbody>
</table>
Peripheral blood smears (cases 1 and 2-NAD, case 3-Microcytic Hypochromic Anemia), Hb-electrophoresis, abdominal ultrasonography and upper GIT endoscopy did not reveal any abnormality. Liver biopsy of all the live cases revealed nonspecific histological findings. In all the three live cases bile obtained from duodenal aspiration contained conjugated bilirubin.

It is known that uridine diphosphate glucuronosyltransferase (UGT) conjugates bilirubin with glucuronic acid in the endoplasmic reticulum of hepatocytes to convert it into water soluble conjugated bilirubin that is excreted in bile. In CNS I the hepatic UGT activity is completely absent. In CNS II less than 10% hepatic UGT activity is retained. Thus CNS I patients suffer from a very severe hyperbilirubinemia that often is fatal in the first few months to two years of life. The type I CNS patients require liver transplantation for survival whereas in CNS II a few residual hepatic UGT activity can be enhanced by Phenobarbitol therapy. CNS II patients are at risk of encephalopathy whenever they are administered anesthetics or certain hepatotoxic drugs or in the presence of septicemia. In CNS II majority of the patients survive unto adulthood without complications (3).

The hepatic UGT activity was not performed in our cases. In all the live three cases (2nd, 3rd and 4th case) Phenobarbital challenge test was done which showed reduced bilirubin levels as shown in Table 2.

<table>
<thead>
<tr>
<th>INVESTIGATION</th>
<th>CASE 2 (CNS II)</th>
<th>CASE 3 (CNS II)</th>
<th>CASE 4 (GS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL BILIRUBIN</td>
<td>BEFORE PB 12.0</td>
<td>BEFORE PB 6.70</td>
<td>BEFORE PB 10.0</td>
</tr>
<tr>
<td>INDIRECT BILIRUBIN</td>
<td>BEFORE PB 11.38</td>
<td>BEFORE PB 3.85</td>
<td>BEFORE PB 1.0</td>
</tr>
<tr>
<td></td>
<td>AFTER PB 4.50</td>
<td>AFTER PB 6.20</td>
<td>AFTER PB 0.9</td>
</tr>
<tr>
<td></td>
<td>AFTER PB 6.70</td>
<td>AFTER PB 1.90</td>
<td>AFTER PB 1.0</td>
</tr>
</tbody>
</table>

Crigler Najjar syndrome comprises two types: Type I CNS and Type II CNS. Type I CNS patients are unaffected by phenobarbitol induction therapy whereas three weeks of phenobarbitol induction therapy can lower bilirubinemia by 60 to 70% in CNS Type II. Treatment of Type II CNS consists of daily phenobarbitol while that of type I requires phototherapy at hospital in early neonatal period then at home for 10 to 12 hours per day. The only effective treatment for type I is liver transplantation (7,8). Children with type I CNS have a permanent risk of neurological complication – kernicterus. Children with type II disease also has this risk but to a lesser extent. Type I CNS occurs with autosomal recessive inheritance. Type II may occur as recessive or dominant trait. Neonates with CNS I have deep icterus and jaundice at or soon after birth that persist and if not treated, it is fatal from first few months to two years of life. In CNS II jaundice may not manifest until later in infancy or childhood. Phenobarbitol challenge test differentiates between these two types. (11) Phenobarbitol (UGT inducer) reduces serum bilirubin in CNS II to 25% after the second half of first year of life. (12) Serum bilirubin concentration will decrease to normal levels in patients with Gilbert syndrome in contrast to that of CNS I. Whereas no response to phenobarbitol is seen in CNS I. In normal subjects serum bilirubin levels ranges from 0.3 to 1.0 mg/dl, in Gilbert syndrome serum bilirubin rarely exceeds 3-4 mg / dl. In CNS II the bilirubin level ranges from 6 to 20 mg/dl, and in CNS I it ranges from 15 to 50 mg / dl. In our cases conclusively we had excluded all other causes of indirect
Hereditary hyperbilirubinemia and thus the diagnoses of CNS II in second and third case and Gilbert’s Syndrome in the fourth case was established. We felt that the first case in our study had CNS I.

Bilirubin-UGT (1) i.e. UGT1A1 is the only isoform that significantly contributes to the conjugation of bilirubin. Lesions in the gene encoding bilirubin - UGT1A1 result in complete inactivation of the enzyme resulting in Crigler-Najjar Syndrome Type I (CNI). Where as partial inactivation of the enzyme causes Crigler-Najjar Syndrome Type II (CNII). These two syndromes are rare autosomal recessively inherited conditions. (1,2) Inactivation of enzyme leads to accumulation of unconjugated bilirubin in the serum. Severe hyperbilirubinemia as seen in CNI causes bilirubin encephalopathy (Kernicterus). Kernicterus can be fatal in first few months of life or may leave behind permanent neurological sequelae. (1,2) In contrast to Crigler-Najjar syndrome, Gilbert Syndrome is a common inherited condition that is characterized by mild hyperbilirubinemia. (3) An insertion mutation of the TATAA element upstream to UGT1A1 results in a reduced level of expression of the gene. Several structural mutations of UGT1A1 like G71R substitution have been reported to cause mild reduction of UGT activity toward bilirubin causing mild hyperbilirubinemia consistent with Gilbert syndrome (3).

It has been observed that when the normal allele of a heterozygote carrier for Crigler-Najjar type structural mutation contains a Gilbert type promoter, then intermediate levels of hyperbilirubinemia consistent with the diagnosis of CN-II may be observed. (3)

**Genetic workup:**

**Case 2 & case 3**
Clinical diagnosis – Criggler Najjar syndrome Type II
Test performed- Complete sequencing of UGT1A1 gene
Result- Both patients are Homozygous for A[T]7TAA variant in the UGT1A1 gene
Date – 10th Aug2013

**Method**
Genomic DNA was extracted from blood using commercial kits. PCR was performed for the promoter, 5’ untranslated region , all exons (covering intron-exon boundaries) and 3’ untranslated region of the UGT1A1 gene. The PCR was followed by purification using ExoSAP-IT and then Sanger sequencing using Big Dye Terminator sequencing chemistry. Bidirectional Sequencing was performed on automated capillary sequencer (ABI). The sequence chromatograms obtained were compared with wild type.

**Results**
The patients were found to be homozygous for A[T]7TAA variant in the promoter of the UGT1A1 gene. No pathogenic variant was seen in the 5’ untranslated region , all exons (covering intron-exon boundaries) and 3’ untranslated region of the UGT1A1 gene.

**Interpretation**
The persistent jaundice of the patient could be a manifestation of severe form of Gilbert syndrome, provided other known causes of persistent jaundice have been ruled out.

**Case 4:**
Name of patient – Satyendra Kumar 27 years/ male
Name of father – Ram Khilawan, 59 yrs
Name of mother – Geeta Devi , 52 yr
Name of brother – Jeetendra, 30 ys
Clinical diagnosis – Suspected Gilbert syndrome in Satyendra
Date of report – 18th June 2013

**Method**
Genomic DNA was extracted from peripheral blood using commercial extraction kit. The promoter region of UGT1A1 gene was amplified by PCR and sequenced using Sanger method on automated capillary sequencer. BLAST analysis was performed and the TA repeats were manually counted.

**Results**
Satyendra has the following alleles A(TA)7TAA/ A(TA)6TAA; his father has the following alleles - A(TA)7TAA/ A(TA)7TAA; mother has the following alleles - A(TA)7TAA/ A(TA)6TAA and his brother has the following alleles - A(TA)7TAA/A(TA)7TAA.

**Figure 1** showing – Satyendra has the following alleles - A(TA)7TAA/ A(TA)6TAA
**Figure 2:** showing Ram Khilawan(Father) has the following alleles- A(TA)7TAA/A(TA)7TAA
**Figure 3:** showing Geeta Devi (Mother) has the following alleles A(TA)7TAA/ A(TA)6TAA
Figure 4: showing Jeetendra Kumar(Brother) showing the following allele – A(TA)7TAA/A(TA)7TAA

Interpretation
Gilbert syndrome is associated with the polymorphism A(TA)7TAA/A(TA)7TAA in the promoter region of the UGT1A1 gene in most cases. However, in case, other causes of jaundice has been ruled out, the alleles A(TA)7TAA/A(TA)6TAA could also be implicated in Gilbert syndrome. Clinical correlation is suggested

Signed by
Dr Parag Tamhankar, DM, MD, DNB, DCH, FCPS
Scientist D
Genetic Research Center, NIRRH

Thus cases II and III revealed no pathogenic variant of UGT1A1 gene and so have been termed to have severe form of Gilbert’s Syndrome. Clinically the above two cases resembled CNS II that we were tempted to repeat the genetic tests, but the boys’ parents declined for the same.

Case IV was observed to have Gilbert’s Syndrome.

IV. Treatment aspect:
CNS I requires orthotopic liver transplantation(14) and until then phototherapy to combat the high levels of serum bilirubin (7,8). Phototherapy is not possible life long because as age advances the skin becomes thick and light cannot pass effectively. Gene repair therapy is still in experimental stage.(13)

It is commonly thought that CNS II patients do not require treatment but these patients should take adequate precautions as for hepatotoxic drugs, anaesthetics and septicemia etc. Also some patients are aware of their jaundiced skin, in such cases low doses of phenobarbitol helps in inducing UGT1A1 and reducing indirect hyperbilirubinemia.(7,8).

V. Conclusion:
It is very important to discover a new effective, long acting and safe drug that induces UGT1A1 in CNS II and Gilbert syndrome ‘s patients. Patients should be well educated about their disease and counseled.

References:
[1]. Analysis of Bilirubin uridine 5 -1- diphosphate(UDP) glucuronosyl transferase gene mutatins.[J Human gene1998]
[2]. Spectrum of UGT1A1 mutations in C N S patients.[Hum Mutat.2005]
[3]. Genetic polymorphism of bilirubin uridine diphospha te gluuronosyl transferase.[J Gast roenterology,Hepa 2004]
[4]. (Review)Genetic lesion of bilirubin uridine diphosphate glucuronosyl transferase.[Human Mutat.2000]
Hereditary hyperbilirubinemia: An original study of four cases with review of literature.

